View On Demand

A Major Breakthrough In Women’s Reproductive Health

About the Event

Each year 500,000 women in the United States opt for a tubal ligation to prevent future pregnancies. This expensive procedure is currently the only available method of permanent female contraception and requires hospitalization, surgery, anesthesia, and a long recovery time.

AltaScience, a Dublin-based medical technology company, has developed a permanent, removable intra-tubal contraceptive device that is painlessly implanted in a gynecologist’s office without anesthesia in a matter of minutes. Based on the Celt Arterial Closure Device which has been proven in over 90,000 patients, AltaSeal IV Micro-Insert has been in development since 2013 and undergone proof of concept testing in 84 women over the past 5 years with no pregnancies or serious adverse events.
Based on this success, AltaScience is now moving towards an IDE submission with the FDA in preparation for clinical trials.

Join our webinar to hear from AltaScience CEO, David O’Flynn, as he talks about the significant breakthrough the AltaSeal IV Micro-Insert represents in reproductive health, and the opportunity it offers for millions of women looking for an alternative to tubal ligation.

View On-Demand Event


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.